Lupus & antiphospholipid syndrome
Local immune effector cell-associated toxicity syndrome in chimeric antigen receptor (CAR) T-cell treated patients with autoimmune disease: an observational study
Authors' conclusion
LICATS is a new form of toxicity in patients with autoimmune disease receiving CD19-targeting CAR T-cell therapy, most likely based on the cleansing of immune cells from the affected organs. It is self-limited, organ-specific, and usually mild in its intensity.
Study context
- Population
- Patients of any age with autoimmune disease receiving CD19-targeting CAR T-cell therapy, two centres in Germany, March 2021–Oct 202425 (64%) female
- Participants
- 39 patients
- Exposure
- Systemic lupus erythematosus (SLE) vs SSc vs IIM
- SLEn = 20
- SScn = 13
- IIMn = 6
- Outcome
- Local organ-specific reactions after CAR T-cell infusion (LICATS), graded for severity
Methodological detailstwo centres in Germany, follow-up of at least 30 days, People with related lived experience were involved in the study design and implementation
- Two centres in Germany
- Follow-up of at least 30 days
- People with related lived experience were involved in the study design and implementation
Main finding
As reported in the abstract
LICATS (local immune effector cell-associated toxicity syndrome)
- Local reactions recorded
- 54
- Patients affected
- 30 (77%)
- Median time of onset from infusion, days (IQR 9-21)
- 10
- Median duration, days (5-14)
- 11
- Skin affected, of 54
- 19 [35%]
- Kidneys affected
- 12 [22%]
- Grade 1
- 35 [65%]
- Grade 2
- 16 [30%]
Observational data: associations, not effects.
Original publication
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. Published 30 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →